ALNY · Alnylam Pharmaceuticals, Inc. · Earnings Call Transcripts & Audio
$246.74
-7.33 (-2.89%)
At close · Sep 30
Return incl. dividend (before tax)
Market Cap
$34.17B
Shares
133.81M
Volume · Sep 30
1.04M
Avg daily vol (3M)
1.8M
Alnylam Pharmaceuticals, Inc. Earnings Call Transcripts
Quarterly earnings calls for Alnylam Pharmaceuticals, Inc. (ALNY), with available speaker-labelled transcripts, captured audio replays, call highlights, 8-K earnings releases and periodic filings. Investor days and conferences appear here too.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
▲40.9%
$264.31M
−$405.92M
'22 Q3
22-10-27
▲29.6%
$335.04M
−$207.49M
'22 Q4
23-02-23
▲49.7%
$319.29M
−$174.10M
'23 Q1
23-05-04
▲41.8%
$318.75M
−$276.02M
'23 Q2
23-08-03
▲184%
$750.53M
$147.75M
'23 Q3
23-11-02
▲31.2%
$439.72M
−$137.87M
'23 Q4
24-01-08
▲54.8%
$494.33M
−$65.94M
'24 Q1
24-03-31
▲107%
$659.83M
−$16.89M
'24 Q2
24-06-30
▼33.3%
$500.92M
−$111.57M
'24 Q3
24-09-30
▲34.9%
$593.17M
−$83.76M
'24 Q4
25-01-13
▲20.2%
$594.19M
−$18.25M
'25 Q1
25-03-31
▲17.3%
$773.69M
−$72.23M
'25 Q2
25-07-31
▲149.3%
$1.25B
$251.08M
'25 Q3
25-10-30
▲84.9%
$1.10B
$153.14M
'25 Q4
26-02-12
LATEST
▲66.9%
$1.29B
$164.49M
'26 Q2
26-07-30
Conference
Investor event
2026-09-14
Alnylam Pharmaceuticals, Inc. (ALNY) September 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-09-08
Alnylam Pharmaceuticals, Inc. (ALNY) September 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q2
2026-07-30
Alnylam Pharmaceuticals, Inc. (ALNY) Q2 2026 Earnings Call Transcript
Confident tone
Amvutra TTR franchise performance
Triton-CM cardiovascular outcomes trial
Market size and disease awareness
Revenue
$1.29B
▲ 66.9% YoY Diluted EPS
$1.21
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-06-09
Alnylam Pharmaceuticals, Inc. (ALNY) June 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-05-13
Alnylam Pharmaceuticals, Inc. (ALNY) May 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q1
2026-04-30
Alnylam Pharmaceuticals, Inc. (ALNY) Q1 2026 Earnings Call Transcript
Confident tone
TTR franchise growth and AMVUTTRA launch
Pipeline progress and RNAi platform
International TTR dynamics (Japan, Germany)
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-02-12
Alnylam Pharmaceuticals, Inc. (ALNY) Q4 2025 Earnings Call Transcript
Confident tone
TTR franchise / Amvuttra launch
Alnylam 2030 strategic goals
Pipeline & R&D platform
Revenue
$1.10B*
▲ 84.9% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-10-30
Alnylam Pharmaceuticals, Inc. (ALNY) Q3 2025 Earnings Call Transcript
Confident tone
AMVUTTRA cardiomyopathy (ATTR-CM) launch
TTR franchise revenue growth
International expansion (Japan, Germany, Europe)
Revenue
$1.25B
▲ 149.3% YoY Diluted EPS
$1.84
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-07-31
Alnylam Pharmaceuticals, Inc. (ALNY) Q2 2025 Earnings Call Transcript
Confident tone
TTR franchise and ATTR-CM launch
Commercial revenue growth and guidance raise
Payer access and reimbursement
Revenue
$773.69M
▲ 17.3% YoY Diluted EPS
$-0.55
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-03-31
Alnylam Pharmaceuticals, Inc. (ALNY) Q1 2025 Earnings Call Transcript
Confident tone
TTR franchise and ATTR-CM launch
Pipeline and portfolio expansion
Access, payer dynamics and step edits
Revenue
$594.19M
▲ 20.2% YoY Diluted EPS
$-0.14
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-01-13
Alnylam Pharmaceuticals, Inc. (ALNY) Q4 2024 Earnings Call Transcript
Confident tone
TTR franchise commercial performance
ATTR cardiomyopathy launch
Pipeline and R&D
Revenue
$593.17M*
▲ 34.9% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-09-30
Alnylam Pharmaceuticals, Inc. (ALNY) Q3 2024 Earnings Call Transcript
Confident tone
ATTR cardiomyopathy launch preparation
Pipeline expansion and CNS progress
TTR franchise growth
Revenue
$500.92M
▼ 33.3% YoY Diluted EPS
$-0.87
▼ 175.7% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-06-30
Alnylam Pharmaceuticals, Inc. (ALNY) Q2 2024 Earnings Call Transcript
Confident tone
HELIOS-B Phase 3 results for vutrisiran in ATTR-CM
Commercial TTR franchise performance (AMVUTTRA/ONPATTRO)
Regulatory and pricing/ICER considerations
Revenue
$659.83M
▲ 107% YoY Diluted EPS
$-0.13
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-03-31
Alnylam Pharmaceuticals, Inc. (ALNY) Q1 2024 Earnings Call Transcript
Confident tone
TTR franchise / AMVUTTRA commercial performance
HELIOS-B Phase III readout
Zilebesiran hypertension program
Revenue
$494.33M
▲ 54.8% YoY Diluted EPS
$-0.52
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-01-08
Alnylam Pharmaceuticals, Inc. (ALNY) Q4 2023 Earnings Call Transcript
Confident tone
TTR franchise growth (ONPATTRO/AMVUTTRA)
2024 financial guidance / P5x25 strategy
Competitive positioning vs tafamidis and eplontersen
Revenue
$439.72M*
▲ 31.2% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-02
Alnylam Pharmaceuticals, Inc. (ALNY) Q3 2023 Earnings Call Transcript
Revenue
$750.53M
▲ 184% YoY Diluted EPS
$1.15
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-03
Alnylam Pharmaceuticals, Inc. (ALNY) Q2 2023 Earnings Call Transcript
Revenue
$318.75M
▲ 41.8% YoY Diluted EPS
$-2.21
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-04
Alnylam Pharmaceuticals, Inc. (ALNY) Q1 2023 Earnings Call Transcript
Revenue
$319.29M
▲ 49.7% YoY Diluted EPS
$-1.40
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-02-23
Alnylam Pharmaceuticals, Inc. (ALNY) Q4 2022 Earnings Call Transcript
Revenue
$335.04M*
▲ 29.6% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-10-27
Alnylam Pharmaceuticals, Inc. (ALNY) Q3 2022 Earnings Call Transcript
Revenue
$264.31M
▲ 40.9% YoY Diluted EPS
$-3.32
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-07-28
Alnylam Pharmaceuticals, Inc. (ALNY) Q2 2022 Earnings Call Transcript
Revenue
$224.82M
▲ 1.9% YoY Diluted EPS
$-2.29
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-04-28
Alnylam Pharmaceuticals, Inc. (ALNY) Q1 2022 Earnings Call Transcript
Revenue
$213.26M
▲ 20.1% YoY Diluted EPS
$-2.00
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-02-10
Alnylam Pharmaceuticals, Inc. (ALNY) Q4 2021 Earnings Call Transcript
Revenue
$258.54M*
▲ 58.1% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-10-28
Alnylam Pharmaceuticals, Inc. (ALNY) Q3 2021 Earnings Call Transcript
Revenue
$187.63M
▲ 49.1% YoY Diluted EPS
$-1.72
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-08-03
Alnylam Pharmaceuticals, Inc. (ALNY) Q2 2021 Earnings Call Transcript
Revenue
$220.55M
▲ 112.1% YoY Diluted EPS
$-1.61
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-04-29
Alnylam Pharmaceuticals, Inc. (ALNY) Q1 2021 Earnings Call Transcript
Revenue
$177.57M
▲ 78.5% YoY Diluted EPS
$-1.71
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-02-11
Alnylam Pharmaceuticals, Inc. (ALNY) Q4 2020 Earnings Call Transcript
Revenue
$163.56M
▲ 128.2% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-11-05
Alnylam Pharmaceuticals, Inc. (ALNY) Q3 2020 Earnings Call Transcript
Revenue
$125.85M
▲ 79.6% YoY Diluted EPS
$-2.18
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-08-06
Alnylam Pharmaceuticals, Inc. (ALNY) Q2 2020 Earnings Call Transcript
Revenue
$103.96M
▲ 132.5% YoY Diluted EPS
$-1.56
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-05-06
Alnylam Pharmaceuticals, Inc. (ALNY) Q1 2020 Earnings Call Transcript
Revenue
$99.48M
▲ 198.8% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY19 · Q4
2020-02-06
Alnylam Pharmaceuticals, Inc. (ALNY) Q4 2019 Earnings Call
Revenue
$71.68M
▲ 240.8% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Showing 1–31 of 31 earnings calls
Key facts
CIK
1178670
CUSIP
02043Q107
13F (30d)
20 filings
16 filers
Visit website
Investor relations